vidarabine phosphate has been researched along with Adenocarcinoma in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (25.00) | 18.7374 |
1990's | 2 (50.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Both, GW; Dane, A; Jeyakumar, G; Martiniello-Wilks, R; Mortensen, E; Russell, PJ; Shaw, JM; Voeks, DJ; Wang, XY | 1 |
Clark, G; Hersh, M; Hutton, JJ; Kuhn, J; Phillips, J; Von Hoff, DD | 1 |
Ashenhurst, JB; Benson, AB; Blough, RR; French, SL; Kilton, LJ; Schilsky, RL; Shiomoto, G; Wade, JL | 1 |
Benson, AB; Blough, R; French, S; Greenberg, A; Johnson, P; Kilton, LJ; Shapiro, C; Weidner, L | 1 |
2 trial(s) available for vidarabine phosphate and Adenocarcinoma
Article | Year |
---|---|
Phase II study of fludarabine phosphate for gastric adenocarcinoma. An Illinois Cancer Center trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Female; Humans; Injections, Intravenous; Male; Middle Aged; Stomach Neoplasms; Vidarabine Phosphate | 1994 |
Phase II trial of fludarabine phosphate for adenocarcinoma of the pancreas. An Illinois Cancer Center study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Vidarabine Phosphate | 1992 |
2 other study(ies) available for vidarabine phosphate and Adenocarcinoma
Article | Year |
---|---|
Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease.
Topics: Adenocarcinoma; Adenoviridae; Animals; Animals, Genetically Modified; Antimetabolites, Antineoplastic; Disease Models, Animal; Escherichia coli; Female; Genetic Therapy; Infusions, Parenteral; Male; Mice; Mice, Inbred C57BL; Prodrugs; Prostate; Prostatic Neoplasms; Purine-Nucleoside Phosphorylase; Survival Analysis; Vidarabine Phosphate | 2004 |
Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate (NSC 312887), a new purine antimetabolite.
Topics: Adenocarcinoma; Arabinonucleotides; Drug Evaluation; Female; Humans; Kinetics; Lung Neoplasms; Male; Neoplasms; Vidarabine; Vidarabine Phosphate | 1984 |